Karyopharm, Menarini Get Positive CHMP Opinion for Nexpovio in Multiple Myeloma

By Michael Dabaie

Karyopharm Therapeutics Inc. and private pharmaceutical company Menarini Group said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Nexpovio, or selinexor, in multiple myeloma.

The opinion was for Nexpovio in combination with once weekly bortezomib and low-dose dexamethasone for adults with multiple myeloma who have received one to three prior lines of therapy.

The positive CHMP opinion is a scientific recommendation for marketing authorization and one of the final steps before the European Commission makes a decision on Karyopharm's Nexpovio application.

The companies expect the EC's decision about 60 days following the CHMP recommendation.

In December 2021, Karyopharm and Menarini Group entered into an exclusive license agreement to commercialize Nexpovio in Europe.

Write to Michael Dabaie at [e-mail]

(END) Dow Jones Newswires

05-20-22 0926ET